Blue Trust Inc. Cuts Stock Holdings in Koninklijke Philips N.V. (NYSE:PHG)

Blue Trust Inc. reduced its position in shares of Koninklijke Philips N.V. (NYSE:PHG) by 38.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,391 shares of the technology company’s stock after selling 2,153 shares during the period. Blue Trust Inc.’s holdings in Koninklijke Philips were worth $86,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in PHG. Colonial Trust Co SC raised its holdings in Koninklijke Philips by 724.0% during the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company’s stock worth $36,000 after purchasing an additional 1,238 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Koninklijke Philips by 37.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company’s stock valued at $54,000 after buying an additional 582 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Koninklijke Philips in the fourth quarter valued at about $55,000. Millstone Evans Group LLC purchased a new position in Koninklijke Philips in the fourth quarter valued at about $60,000. Finally, Smartleaf Asset Management LLC increased its holdings in Koninklijke Philips by 177.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,489 shares of the technology company’s stock valued at $114,000 after buying an additional 2,871 shares in the last quarter. 13.67% of the stock is owned by hedge funds and other institutional investors.

Koninklijke Philips Trading Up 0.0%

Shares of PHG opened at $23.91 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.28 and a quick ratio of 0.79. Koninklijke Philips N.V. has a 1-year low of $20.61 and a 1-year high of $31.57. The stock has a market cap of $23.02 billion, a price-to-earnings ratio of 55.61, a price-to-earnings-growth ratio of 0.68 and a beta of 0.76. The firm has a 50 day simple moving average of $23.70 and a 200-day simple moving average of $25.08.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.13. Koninklijke Philips had a return on equity of 10.97% and a net margin of 2.11%. The firm had revenue of $4.31 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the firm earned $0.21 EPS. Koninklijke Philips’s quarterly revenue was down 1.0% on a year-over-year basis. Equities analysts forecast that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Sanford C. Bernstein raised shares of Koninklijke Philips from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 18th. Wall Street Zen cut shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Sunday, June 15th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.